PCI allows institutions to restore admission intake to previous year levels

New Delhi, October 28, 2022:

The Pharmacy Council of India (PCI) has decided to restore the student intake to the levels of the previous year, to those colleges which faced a reduction in admission intake for the year 2022-23 academic session. It has also sought the institutions to submit an affidavit agreeing to subject itself for verification by the PCI and agreeing to the action from the Council in case of non-compliance or false/fraudulent activities in connection to this.

In an Executive Committee meeting held on October 15, 2022, the Council has decided that wherever admission intake was reduced in 2022-23 academic session in pharmacy courses, the previously approved intake during 2021-22 academic session be restored for 2022-23 academic session also.

It has also decided to notify all such institutes that an affidavit should be uploaded on the institution's dashboard on the portal of PCI, New Delhi, within one month of receipt of the notification without fail.

“There should not be any change/modification/alteration in the affidavit provided with this notification. In case any change is observed, the same will not be entertained at any cost and the liabilities will rest only with the Institute and not PCI,” said the PCI notification.

In view of this, all institutions are directed to submit the prescribed affidavit along with their appeal application, and update the faculty data on PCI portal within one month of receipt of the notification. The information to be submitted include the increase in intake, which is applicable in case institution has applied earlier at the time of submission of the Standard Inspection Format (SIF) for the year 2022-23; introduction of new course such as D Pharm, B Pharm, M Pharm, Pharm D, Pharm D (PB) and B Pharm (practice); and restoration of reduced seats.

The institutes need to submit the affidavit on aRs 100 non judicial stamp paper that in case approval is granted or the admissions are restored for the year 2022-23, the same is subject to verification of the compliance report by the PCI at any later date.

In case compliance is found to be false/un-satisfactory/fraudulent/misleading, the principal or the head of institution and Department Secretary of the State government in case of Government Institutions, or those who are signatory to the affidavit will be liable for action as per the law of the country.

“PCI may initiate action as deemed fit including notice under Section 13(1) of the Pharmacy Act, 1948 for withdrawal of approval and the consequences thereof and the responsibility will rest on the Institution itself and PCI shall not be held responsible for this,” says the format of the affidavit to be submitted by the pharmacy institutions as part of restoration of the admission intake in lines with their previous submission.

The PCI has earlier prescribed a format for the appeal process for the institutions if the decision of approval for the academic session 2022-23 communicated by the Council was not satisfactory. PharmaNews